Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Steven Kyle Grinspoon, M.D.

Co-Author

This page shows the publications co-authored by Steven Grinspoon and Michael Lu.
Connection Strength

2.178
  1. Individual coronary plaque changes on serial CT angiography: Within-patient heterogeneity, natural history, and statin effects in HIV. J Cardiovasc Comput Tomogr. 2020 Mar - Apr; 14(2):144-148.
    View in: PubMed
    Score: 0.213
  2. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019 06; 212:23-35.
    View in: PubMed
    Score: 0.206
  3. Mild renal impairment is associated with calcified plaque parameters assessed by computed tomography angiography in people living with HIV. AIDS. 2019 02 01; 33(2):219-227.
    View in: PubMed
    Score: 0.205
  4. Differential relationships of hepatic and epicardial fat to body composition in HIV. Physiol Rep. 2017 Oct; 5(19).
    View in: PubMed
    Score: 0.188
  5. Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals. J Infect Dis. 2017 04 15; 215(8):1264-1269.
    View in: PubMed
    Score: 0.181
  6. Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. AIDS. 2016 09 10; 30(14):2205-14.
    View in: PubMed
    Score: 0.174
  7. Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection. JAMA Cardiol. 2016 07 01; 1(4):474-80.
    View in: PubMed
    Score: 0.172
  8. Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus. Open Forum Infect Dis. 2016 Apr; 3(2):ofw062.
    View in: PubMed
    Score: 0.171
  9. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015 Feb; 2(2):e52-63.
    View in: PubMed
    Score: 0.155
  10. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014 Sep 10; 28(14):2061-70.
    View in: PubMed
    Score: 0.151
  11. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Netw Open. 2021 Jun 01; 4(6):e2114923.
    View in: PubMed
    Score: 0.060
  12. Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S20-S30.
    View in: PubMed
    Score: 0.057
  13. Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity (Silver Spring). 2020 04; 28(4):749-755.
    View in: PubMed
    Score: 0.055
  14. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019 06; 212:1-12.
    View in: PubMed
    Score: 0.052
  15. Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. J Acquir Immune Defic Syndr. 2018 05 01; 78(1):105-110.
    View in: PubMed
    Score: 0.049
  16. Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV. Circ Cardiovasc Imaging. 2017 10; 10(10).
    View in: PubMed
    Score: 0.047
  17. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. AIDS. 2016 Feb 20; 30(4):583-90.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.